BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

780 related articles for article (PubMed ID: 35062368)

  • 1. Immune Profiling of COVID-19 in Correlation with SARS and MERS.
    Khalil BA; Shakartalla SB; Goel S; Madkhana B; Halwani R; Maghazachi AA; AlSafar H; Al-Omari B; Al Bataineh MT
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile of Circulatory Cytokines and Chemokines in Human Coronaviruses: A Systematic Review and Meta-Analysis.
    Zawawi A; Naser AY; Alwafi H; Minshawi F
    Front Immunol; 2021; 12():666223. PubMed ID: 34046036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
    Jafarzadeh A; Chauhan P; Saha B; Jafarzadeh S; Nemati M
    Life Sci; 2020 Sep; 257():118102. PubMed ID: 32687918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MERS-CoV infection is associated with downregulation of genes encoding Th1 and Th2 cytokines/chemokines and elevated inflammatory innate immune response in the lower respiratory tract.
    Alosaimi B; Hamed ME; Naeem A; Alsharef AA; AlQahtani SY; AlDosari KM; Alamri AA; Al-Eisa K; Khojah T; Assiri AM; Enani MA
    Cytokine; 2020 Feb; 126():154895. PubMed ID: 31706200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.
    Coperchini F; Chiovato L; Croce L; Magri F; Rotondi M
    Cytokine Growth Factor Rev; 2020 Jun; 53():25-32. PubMed ID: 32446778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
    Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
    Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
    Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
    Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.
    Yao Z; Zheng Z; Wu K; Junhua Z
    Aging (Albany NY); 2020 May; 12(9):7639-7651. PubMed ID: 32364527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative review of pathogenesis and host innate immunity evasion strategies among the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV).
    Noor R
    Arch Microbiol; 2021 Jul; 203(5):1943-1951. PubMed ID: 33682075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.
    Atzrodt CL; Maknojia I; McCarthy RDP; Oldfield TM; Po J; Ta KTL; Stepp HE; Clements TP
    FEBS J; 2020 Sep; 287(17):3633-3650. PubMed ID: 32446285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 Causes a Different Cytokine Response Compared to Other Cytokine Storm-Causing Respiratory Viruses in Severely Ill Patients.
    Olbei M; Hautefort I; Modos D; Treveil A; Poletti M; Gul L; Shannon-Lowe CD; Korcsmaros T
    Front Immunol; 2021; 12():629193. PubMed ID: 33732251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Immune Response between SARS, MERS, and COVID-19 Infection, Perspective on Vaccine Design and Development.
    Ansariniya H; Seifati SM; Zaker E; Zare F
    Biomed Res Int; 2021; 2021():8870425. PubMed ID: 33564683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
    Wooding DJ; Bach H
    Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lethal internal face of the coronaviruses: Kidney tropism of the SARS, MERS, and COVID19 viruses.
    Motavalli R; Abdelbasset WK; Rahman HS; Achmad MH; Sergeevna NK; Zekiy AO; Adili A; Khiavi FM; Marofi F; Yousefi M; Ghoreishizadeh S; Shomali N; Etemadi J; Jarahian M
    IUBMB Life; 2021 Aug; 73(8):1005-1015. PubMed ID: 34118117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronaviruses: Innate Immunity, Inflammasome Activation, Inflammatory Cell Death, and Cytokines.
    Lee S; Channappanavar R; Kanneganti TD
    Trends Immunol; 2020 Dec; 41(12):1083-1099. PubMed ID: 33153908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human and novel coronavirus infections in children: a review.
    Rajapakse N; Dixit D
    Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Immune Responses against Coronavirus Infections: Friend or Foe?
    Vafaeinezhad A; Atashzar MR; Baharlou R
    Int Arch Allergy Immunol; 2021; 182(9):863-876. PubMed ID: 33951640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us.
    Kumar V
    Int Rev Immunol; 2021; 40(1-2):5-53. PubMed ID: 32744465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remdesivir against COVID-19 and Other Viral Diseases.
    Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type I IFNs: A Blessing in Disguise or Partner in Crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-Induced Pathology and Potential Use of Type I IFNs in Synergism with IFN-
    Anjum FR; Anam S; Abbas G; Mahmood MS; Rahman SU; Goraya MU; Abdullah RM; Luqman M; Ali A; Akram MK; Chaudhry TH
    Viral Immunol; 2021 Jun; 34(5):321-329. PubMed ID: 33181057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.